We are live on
!
Find out more
RL
Ruffer LLP Portfolio holdings
AUM
$2.44B
1-Year Est. Return
44.75%
This Fund
S&P 500
This Quarter
Est. Return
+18.22%
1 Year Est. Return
+44.75%
3 Year Est. Return
+105.9%
5 Year Est. Return
+158.64%
10 Year Est. Return
+642.68%
AUM
$3.43B
AUM Growth
-$91.6M
(-2.6%)
Cap. Flow
-$572M
Cap. Flow
% of AUM
-16.67%
Top 10 Holdings %
Top 10 Hldgs %
62.86%
Holding
98
New
5
Increased
18
Reduced
40
Closed
17
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Bristol-Myers Squibb
BMY
|
+$294M |
| 2 |
Freeport-McMoran
FCX
|
+$172M |
| 3 |
eHealth
EHTH
|
+$76.5M |
| 4 |
Dow Inc
DOW
|
+$55.4M |
| 5 |
General Motors
GM
|
+$38.8M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
CELG
Celgene Corp
CELG
|
+$318M |
| 2 |
Amgen
AMGN
|
+$218M |
| 3 |
Walt Disney
DIS
|
+$133M |
| 4 |
ATVI
Activision Blizzard
ATVI
|
+$111M |
| 5 |
Cigna
CI
|
+$108M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Materials | 32.47% |
| 2 | Healthcare | 23.38% |
| 3 | Communication Services | 13.54% |
| 4 | Energy | 13.02% |
| 5 | Consumer Discretionary | 7.46% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
DRD
26
DRDGold
DRD
$1.82B
| $26.5M | 0.77% |
5,166,088
| – | – |
|
27
Jefferies Financial Group
JEF
$12.9B
| $25.9M | 0.76% |
1,266,307
-135,512
| -10% | -$2.56M |
|
|
GAU
28
Galiano Gold
GAU
$486M
| $20.4M | 0.6% |
21,818,789
+1,021,600
| +5% | +$907K |
|
|
IMV
29
DELISTED
IMV Inc. Common Shares
IMV
| $19.8M | 0.58% |
680,123
| – | – |
|
30
Cemex
CX
$17.4B
| $16.1M | 0.47% |
4,238,160
+2,938,160
| +226% | +$11.2M |
|
31
McKesson
MCK
$98.5B
| $15.7M | 0.46% |
113,641
-738,448
| -87% | -$104M |
|
32
Alibaba
BABA
$269B
| $14.9M | 0.43% |
70,000
+42,000
| +150% | +$7.88M |
|
33
M&T Bank
MTB
$36.2B
| $12.9M | 0.38% |
76,171
+21,072
| +38% | +$3.42M |
|
|
BMY.RT
34
DELISTED
Bristol-Myers Squibb Company Contingent Value Rights
BMY.RT
| $11.3M | 0.33% |
+3,658,126
| New | +$9.51M |
|
35
Fortuna Silver Mines
FSM
$2.59B
| $10.5M | 0.31% |
2,560,983
+873,368
| +52% | +$2.86M |
|
36
Harmony Gold Mining
HMY
$9.92B
| $9.9M | 0.29% |
2,729,785
| – | – |
|
37
Aptiv
APTV
$12B
| $9.83M | 0.29% |
103,483
-27,995
| -21% | -$2.56M |
|
|
DLPH
38
DELISTED
Delphi Technologies PLC Ordinary Shares
DLPH
| $8.35M | 0.24% |
649,804
-1,375
| -0.2% | -$17.8K |
|
39
Microsoft
MSFT
$2.84T
| $5.26M | 0.15% |
33,385
-12,074
| -27% | -$1.77M |
|
|
ALO
40
DELISTED
Alio Gold Inc
ALO
| $4.35M | 0.13% |
5,526,793
| – | – |
|
|
USAS
41
Americas Gold and Silver
USAS
$1.34B
| $4.12M | 0.12% |
519,797
| – | – |
|
42
Apple
AAPL
$4.89T
| $3.56M | 0.1% |
48,532
-58,296
| -55% | -$3.75M |
|
|
GPL
43
DELISTED
Great Panther Mining Limited
GPL
| $3.13M | 0.09% |
610,668
| – | – |
|
|
44
Amgen
AMGN
$203B
| $2.79M | 0.08% |
11,561
-991,194
| -99% | -$218M |
|
45
Tenaris
TS
$29.1B
| $2.66M | 0.08% |
117,323
-10,501
| -8% | -$226K |
|
46
BlackBerry
BB
$5.01B
| $2.41M | 0.07% |
375,000
+137,500
| +58% | +$755K |
|
|
CHX
47
DELISTED
ChampionX
CHX
| $2.28M | 0.07% |
67,484
-47,832
| -41% | -$1.3M |
|
48
Philip Morris
PM
$301B
| $1.87M | 0.05% |
22,000
-2,500
| -10% | -$206K |
|
49
Mohawk Industries
MHK
$6.9B
| $1.64M | 0.05% |
12,000
| – | – |
|
50
NXP Semiconductors
NXPI
$68B
| $1.61M | 0.05% |
12,662
-12,394
| -49% | -$1.44M |
|
Similar funds
QT
TMC
GWM
KFA
BW
M
BBA
PUI
Ruffer LLP's Q4 2019 Portfolio in Review
As of Q4 2019, Ruffer LLP held 98 positions worth $3.43B, down 2.6% from $3.52B the previous quarter. Its ten largest holdings account for 63% of the portfolio.
Ruffer LLP withdrew a net $572M in Q4 2019, closing 17 positions and reducing 40 holdings. Its most notable exit was Celgene Corp, an estimated $318M position sold in full.
By sector, the portfolio is most concentrated in Materials at 32% of assets, up from 24% a quarter earlier, followed by Healthcare and Communication Services.
Against the trend, Ruffer LLP opened a new position in eHealth worth $94.7M.
- Ruffer LLP's largest Q4 2019 buy was eHealth: 985,957 shares worth $94.7M.
- Ruffer LLP added most to Bristol-Myers Squibb in Q4 2019, an estimated $294M increase.
- Ruffer LLP's biggest Q4 2019 reduction was Amgen, cutting an estimated $218M.
- Ruffer LLP fully exited Celgene Corp in Q4 2019, selling an estimated $318M.
- Ruffer LLP's ten largest holdings make up 63% of its $3.43B portfolio in Q4 2019.
- Ruffer LLP opened 5 new positions and closed 17 in Q4 2019.
- Ruffer LLP's portfolio value fell 2.6% quarter-over-quarter to $3.43B.
Based on Ruffer LLP's 13F filing for Q4 2019, filed 6 Feb 2020.